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ABSTRACT
Diabetes mellitus (DM) is a metabolic syndrome characterized by hyperglycemia and glucose intolerance, due to
insulin resistance, insulin deficiency, or both. Diabetics retinopathy (DR) is a DM complication due to retinal abnormality,
that causes vision reduction and even blindness. The association between DR and aldose reductase C-106T (ALR C-
106T) gene polymorphism has been reported in previous studies. This genetic polymorphism increases the sorbitol
level inside erythrocyte and pericyte in the retinal membrane that leads to weakness of retinal capillary vessel and
microaneurism. The aim of this study was to know the presence of ALR C-106T gene polymorphism and its frequency
distribution among diabetics Javanese patients in Dr. Sardjito General Hospital Yogyakarta, Indonesia. In addition,
this study also aimed to analyze the difference of erythrocytes osmotic fragility (EOF) among ALR genotypes in type
2 diabetics patients  with DR and without DR and to analyze whether ALR genetic polymorphism is a risk factor of
DR in type 2 diabetic patients. This was a case control study that involved 40 diabetics patients with DR as case and
40 diabetics patients without DR as control groups. The C-106T ALR gene polymorphism was determined by
polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method. Erythrocytes osmotic
fragility was analyzed using spectrophotometer. Genotype and allele distributions were analyzed using x2 and other
data were analyzed using independent t-test and Mann-Whitney, with p<0.05 was considered as significantly
different. The results showed that in type 2 diabetics patients with DR, 33 patients (82.5%) were CC homozygote
individuals and 7 patients (17.5%) were CT heterozygote individuals. In type 2 diabetics patients without DR, 27
patients (67.5%) were CC homozygote individuals and 13 patients (32.5 %) were CT heterozygote individuals. The
genotype and allele distributions were not significantly different between two groups (p=0.121 for genotype,
p=0.151 for allele). Odds Ratio of genotype was 2.270 while allele was 2.023. Erythrocytes osmotic fragility of CC
genotype was higher than CT genotype (p=0.047). In conclusion, there was no significant difference between CC
and CT genotype distribution among type 2 diabetics patients with and without DR. Erythrocyte osmotic fragility of
CC genotype was higher than CT genotype. C-106T gene polymorphism was a risk factor of DR in type 2 diabetic
patients.
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ABSTRAK
Diabetes Mellitus (DM) merupakan penyakit metabolik yang ditandai dengan hiperglikemia dan intoleransi glukosa,
akibat resistensi insulin, kekurangan insulin atau kombinasi keduanya. Retinopati diabetika (RD) adalah komplikasi
DM yang menyebabkan kelainan retina dan berakibat pada penurunan penglihatan bahkan kebutaan. Penelitian
sebelumnya menunjukkan adanya hubungan antara RD dan polimorfisme C-106T gena ALR. Polimorfisme ini
menyebabkan peningkatan kadar sorbitol eritrosit dan membran perisit retina yang berakibat lemahnya pembuluh
kapiler retina dan mikroaneurisme. Penelitian bertujuan mengetahui adanya polimorfisme C-106T gena ALR dan
distribusi frekuensi genotipe dan alel pada suku Jawa di RSUP Dr. Sardjito Yogyakarta. Selain itu juga untuk mengetahui
perbedaan fragilitas osmotik eritrosit antar genotipe, antara DM tipe 2 dengan RD dan tanpa RD serta mengetahui
polimorfisme C-106T gena ALR sebagai faktor risiko RD pada DM tipe 2. Penelitian ini merupakan penelitian kasus
kontrol yang melibatkan 40 pasien DM tipe 2 dengan RD sebagai kasus dan 40 pasien DM tipe 2 tanpa RD sebagai
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kelompok kontrol. Polimorfisme C-106T gena ALR ditentukan dengan metode PCR-RFLP. Fragilitas osmotik di analisa
dengan metode spektrofotometri. Distribusi genotype dan alel dianalisa menggunakan uji x2. Data lainnya dianalisa
menggunakan uji t independen dan Mann-Whitney dengan nilai p<0,05 untuk menentukan perbedaan secara bermakna
hasil analisis.  Hasil penelitian menunjukkan distribusi genotipe pasien DM tipe 2 dengan RD adalah CC 33 (82,5 %),
CT 7 (17,5 %), dan pada pasien DM tipe 2 tanpa RD adalah CC 27 (67,5 %), CT 13 (32,5 %). Distribusi genotipe dan
alel tidak berbeda bermakna antara ke 2 kelompok (p=0,121 untuk genotipe, p=0,151 untuk alel). Rasion Odds
genotipe adalah 2,27, sedangkan alel adalah 2,023. Pada genotipe CC fragilitas osmotik lebih tinggi dibandingkan
CT (p=0,047). Dari hasil penelititan dapat disimpulkan tidak terdapat perbedaan bermakna antara distribusi genotipe
CC dan CT pada pasien DM tipe 2 dengan RD dengan tanpa RD. Fragilitas osmotik eritrosit genotipe CC lebih tinggi
dibandingkan CT. Polimorfisme C-106T gena ALR merupakan faktor risiko RD pada DM tipe 2.
Kata kunci : gena ALR – polimorfisme – DM tipe 2 – retinopati diabetika – fragilitas osmotik eritrosit
INTRODUCTION
 Diabetes mellitus (DM) is a metabolic disease
characterized by hyperglycemia and glucose
intolerance, as a result of insulin deficiency, impaired
insulin action, or combination of both. The
prevalence of DM worldwide is about 4% and is
predicted to continue to increase, and by 2025 will
reach 5.4%.1 World Health Organization (WHO)
has reported the increase number of people with
type 2 DM in Indonesia in 2000 as many as 8.4
millions people and estimated to increase to
approximately 21.3 millions in 2030.2 The
prevalence of DM in Yogyakarta, according to the
national basic health research (RISKESDAS)
Indonesia 2007 was about 1.6 %.
Chronic complications of DM are systemic
vascular disease, heart disease, retinal degeneratur
disease known as diabetic retinopathy, cataracts,
kidney damage and peripheral nerve damage such
as diabetic neuropathy.3 Diabetic retinopathy is a
form of DM complication that causes retinal disorder
which affect vision convulsion until blindness.
Hyperglycemi causes the thickening of retinal blood
vessel and leakage. This complication commonly
happens if its a diabetic patient has never had a
treatment for at least for 15 years.4 In Indonesia,
DR prevalence was 27.2%,5 with 8.7% was in urban
area of Yogyakarta, whereas 7.73% contained in
the rural.6 Ethnic or genetic difference plays a role
in the prevalence of DR.
Damage of the retina caused by hyperglycemia
involves three existing pathways i.e. activation of
the proteins glycation, C kinase protein, and aldose
reductase (ALR).7 Aldose reductase catalyzes the
change of glucose to sorbitol through the reduction
of aldehyde group of glucose. In hyperglycemia,
sorbitol concentration increases and it will be
converted to fructose by sorbitol dehydrogenase
(SDH). In hyperglycemia, sorbitol degradation
proceeds slow, as of accumulates in cells and causes
an increase in osmotic pressure. Excessive
accumulation of sorbitol causes pericytes on retinal
capillaries weakened and causes microaneurism.8
Hemodynamic disturbance in erythrocytes is one
of the causes of blockage and leakage of retinal
blood vessels which is a sign of DR.9 Therefore,
erythrocyte osmotic fragility is used as a parameter
of pericytes retinal cell damage.10
Aldose reductase is coded by ALR gene which
located in the long arm of chromosome 7 (7q35).
This gene codes 316 amino acids and has 10 exon.
The C-106T polymorphism in ALR gene happens
in the basal promoter area and it causes changes in
the expression of mRNA of ALR gene.11 Previous
study showed that C-106T polymorphisms in ALR
gene is strongly associated with DR incidence in
diabetic Chinese. CC genotype carrier strongly
related with risk of DR.12
This study aimed to describe the relation of C-
106T polymorphism in ALR gene with the risk for
DR in diabetic Javanese in Yogyakarta, Indonesia.
In addition, this study also aimed to analyze the
difference of EOF among ALR genotypes in type 2
diabetics patients  with DR and without DR and to
analyze whether ALR genetic polymorphism is a
risk factor of DR in type 2 diabetic patients.
MATERIALS AND METHODS
This was a case-control study. Subjects were
40 type 2 diabetic patients with DR as a case group
and 40 type 2 diabetic patients without DR as a
control group. The inclusion criteria of the research
subject were 1). patient at Dr. Sardjito General
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Hospital Yogyakarta; 2). Javanesse; 3). aged
between 30-65 years old; 4). have been diagnosed
for type 2 diabetes at least for 5 years. The exclusion
criteria were obesity and hypertension. The patients
who fulfilled the inclusion criteria were asked to
sign the informed consent form as their willingness
to become research subject. The protocol of the
study has been approved by the Medical and Health
Research Ethics Committee, Faculty of Medicine,
Gadjah Mada University, Yogyakarta.
Diagnosis of type 2 DM was established based
on fasting blood glucose (FBG) and 2 hours post
prandial blood glucose.2 Retinopathy criteria was
according to fundusphoto which showed one of
retina disorder symptoms (PDR or NPDR). The
acquired data were age, sex, duration of type 2 DM,
body mass index (BMI), blood pressure, and lipid
profile.
Erythrocyte osmotic fragility was checked using
spectrophotometer while lysis percentage and
percentage of NaCl solution which cause 50% of
erythrocyte lysis. Genotyping of C-106T
polymorphism in ALR gene was performed using
PCR-RFLP method. Sample used in this study was
DNA isolated from blood. The PCR conditions were
denaturation at 950C for 2 minutes, followed by 35
cycles of denaturation at 95oC for 60 seconds,
annealing at 67oC for 60 seconds, and extension at
72oC for 60 seconds. The final extension was at
72oC for 5 minutes. The forward primer was: 5’-
CCT TTC TGC CAC GCG GGG CGC GGG-3’
(attached on -222 until - 199) and the reverse primer
was: 5’-CAT GGC TGC TGC GCT CCC CAG-3’
(attached on +21 until starting codon ATG).
Restriction enzyme used in this study was BfaI
(New England Biolabs). The PCR product was
incubated with the BTA for 16 hours. The digestion
product the was then electrophoresed on 2% agarose
gel and visualized by etidium bromide under UV
light. CC genotype had 2 bands: 206 and 57 bp. TT
genotype had 3 bands : 147, 59 and 57 bp, whereas
genotype of CT had 4 bands : 206, 147, 59 and 57
bp.13
RESULTS
Subject characteristics
Subject characteristics are shown in TABLE
1. Subject characteristics such as age, blood pressure,
fasting blood glucose, 2 hours post prandial blood
glucose, serum triglyceride, total cholesterol, HDL
and LDL cholesterol were not significantly different
between type 2 diabetic patients with DR and
without DR (p>0.05). However, the average BMI
of type 2 diabetic patients with DR was lower than
patients without DR (p<0.05).
TABLE 1. Subject characteristics of type 2 diabetic patients. Data  were expressed
in mean ± standard deviation except for sex in %
Variable 
Type 2 DM  p*  
 with DR (n=40) 
without DR 
(n=40) 
Sex    
• Male 16 (40% 15 (37.5%)  
• Female 24 (40%) 25 (62.5%)  
Age   (years) 55.68 ± 7.73 55.33 ± 8.87 0.981 
BMI (kg/m2) 21.90 ± 3.07 23.37 ± 1.83 0.028 
Systolic blood pressure (mmHg) 124.00 ± 11.50 123.50 ± 12.10 0.800 
Diastolic blood pressure (mmHg) 79.25 ± 8.59 80.25 ± 8.00 0.630 
Fasting blood glucose (mg/dL) 168.44 ± 72.48 145.74 ± 66.19 0.128 
2 hours PP blood  glucose (mg/dL) 236.82 ± 75.17 214.57 ± 91.59 0.239 
Triglyceride (mg/dL) 122.77 ± 46.30 153.94 ± 127.93 0.954 
Total cholesterol (mg/dL) 178.35 ± 34.89 173.95 ± 28.42 0.539 
HDL cholesterol  (mg/dL) 75.88 ± 17.31 72.49 ± 13.25 0.207 
LDL cholesterol  (mg/dL) 111.68 ± 23.46 105.65 ± 20.53 0.225 
* Independent t-test and Mann Whitney test with 95% convidence interval (p<0.05)
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C-106T polymorphism in ALR Gene
The genotyping result of C-106T polymorphism
in ALR gene using PCR-RFLP is shown in FIGURE
1. While the distribution of genotype and allele  is
shown in TABLE 2. Genotype distribution of ALR
gene between observed value with expected value
Hardy-Weinberg had no significant difference (p=
0.573). The genotype frequency between type 2
diabetic patients with DR and without DR was not
different (p = 0.121), so as the allele frequency (p
= 0.151). CT genotype  carriers had 2.270 times
increased risk for DR compared with CC genotype
carries, whereas C allele carriers had 2.023 times
increased risk for DR than T allele carriers.
Therefore, the high risk allele for DR in type a
diabetic patients was C allele.
FIGURE 1. Genotyping of C-106T polymorphism in ALR
gene
TABLE 2.  Genotype and allele of type 2 DM risk with DR
Variable 
Type 2 DM  
p* 
 
OR CI (95%) 
with DR (n=40) without DR (n=40) 
Genotype CC 
CT 
33 (82.5%) 
7 (17.5%) 
27 (67.5%) 
13 (32.5%) 0.121 2.270 0.794 – 6.488   
Alelle  C 
T 
73(91.25%) 
7 (8.75%) 
67 (83.75%) 
13 (16.25%) 0.151 2.023 0.762 – 5.374 
*Statistical analysis using Chi square (x2)  test with a 95% confidence interval (p<0.05)
Erythrocyte osmotic fragility
The average percentage of NaCl which caused
lysis of 50% erythrocyte is shown at TABLE 3 and
4. This study showed a significant difference of
erythrocyte osmotic fragility between CC and CT
genotype on type 2 diabetic patients (p=0.047). The
erythrocyte osmotic fragility  increased in CC
genotype individuals (TABLE 3). The percentage of
NaCl on type 2 diabetic patients with DR was higher
than to those without DR (TABLE 4). However, it
was not significantly different (p=0.154).
TABLE 3. The percentage of NaCl (mean ± SD) which caused lysis of 50% erythrocyte based
on the genotype of type 2 diabetic patients with and without DR
Variable Genotype p* CC CT 
NaCl percentage which caused 50% 
lysis of erythrocyte  0.4135 ± 0.0129 0.4067 ± 0.0126 0.047 
* Statistical analysis using Mann-Whitney test with 95% confidence interval (p<0.05)
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TABLE 4. The percentage of NaCl (mean ± SD) difference which caused lyses of 50% erythrocyte between type 2 diabetic
patients  with and without DR
* Statistical analysis using Mann-Whitney test with 95% confidence interval (p<0.05)
DISCUSSION
The subject characteristics of type 2 diabetic
patients with DR and without DR were similar
except BMI. The BMI of type 2 diabetic patients
without DR was higher than those with DR
(p=0.028). The BMI of type 2 diabetic patients is
influenced by prolonged duration of diabetes and
increased insulin resistance which activated lipase-
sensitive hormone, therefore the deposite of
triglyceride in adipose tissue will be hydrolyzed
becomes free fatty acid. This process will decrease
the BMI of type 2 diabetic patients.14
Genotype distribution of C-106T polymorphism
in ALR gene in type 2 diabetic patients in several
populations has been reported by some authors from
different studies (TABLE 5). The studies indicated
that different population showed different genotype
frequency.7,15,16  Diabetic retinopathy development
depends on environment and genetic factors. This
study did not found TT genotype, whereas study in
Euro-Brazil, China, and Chili populations, TT
genotype was found and the number was smaller
than CC and CT genotype. Frequency of CC of
Javanese was higher than other populations (Euro-
Brazil, China and Chili). In type 2 diabetes without
DR, the number of individual with CT genotype
was lower compared to Euro-Brazil and Chili, but
was higher than China.
TABLE 5.   Genotype distribution of C106T polymorphism in ALR gene in type 2 diabetic patients in several populations
Population Subject Genotype* n CC CT TT 
Euro-Brazil  
(Santos et al.16) 
 
DR 
without 
DR 
32 (32.32 %) 
47 (42.73 %) 
46 (46.47 %)  
39 (35.45 %) 
21 (21.21 %) 
24 (21.82 %) 
99 
110 
China 
(Wang et al.17) 
 
DR 
without 
DR 
111 (59.36 %) 
360 (65.34 %) 
 63 (33.69 %) 
163 (29.58 %) 
13 (6.95 %) 
28 (5.08 %) 
187 
551 
Chili 
(Olmos et al.7) 
 
DR 
without 
DR 
24 (45.28 %) 
57 (59.38%) 
26 (49.06 %) 
32 (33.33 %) 
3 (5.66 %) 
7 (7.29 %) 
53 
96 
Jawa 
(this study) 
DR 
without 
DR 
33 (82.5 %) 
27 (67.5 %) 
7 (17.5 %) 
13 (32.5 %) 
0 (0 %) 
0 (0 %) 
40 
40 
* The data were expressed in sum (%); n=total sample
Studies on C-106T polymorphism has showed
a strong association of the polymorphism with DR
complication, although the case and control subjects
had no significant difference.12 For Euro-Brazil
population there was no significant difference
between type 2 diabetic patients with DR and
without DR. CC genotype and C allele were the
high risk genotype and allele for DR complication.
The same result also found in Chili.7
There was correlation between C-106T poly-
morphism with (CA) dinucleotide repetition on ALR
gene promoter region,17 this might happen because
the location of polymorphism was contiguous with
the sequence of ALR gene which causes DR
Variable DM type 2  p* 
with  DR without DR 
NaCl percent which caused lysis of 
50% of erythrocyte  0.4139 ± 0.0110 0.4097 ± 0.0147 0.154 
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sensitivity. From the other research which showed
that CC was a high risk genotype for DR.13
C-106T polymorphism on basal promoter area
of ALR gene will cover the CCAAT promoter
element which located between -98 and -94, in
cases where that region performs as active functional
element. Research showed that CCAAT element
was recognized by nuclear factor of Hep G2 cell.11
Other study showed that different allele on location
-106 would affect the CCAAT element function by
changing the factor binding activity and finally
change the basal transcription level of ALR gene.18
The increase of ALR gene expression was identified
on retinal epithelial cell of CC homozygote carrier
compared with heterozygote genotype CT-106.19
A significant difference of erythrocyte osmotic
fragility between CC and CT genotype on type 2
diabetic patient was observed in this study. The
erythrocyte osmotic fragility  significantly increased
in CC genotype individuals (TABLE 3). Previous
study showed that higher ALR expression occured
in CC genotype individuals compared with CT
genotype individuals.7 The increase also happens
on blood and sorbitol level of erythrocyte on type 2
diabetic patients with DR than without DR.20
Sorbitol accumulation will affect osmolality of
erythrocyte and causes its fragility to increase.
Higher percentage of NaCl on type 2 diabetic
patients with DR indicated a higher erythrocyte
fragility compared to those without DR. High level
of plasma glucose can affect osmotic pressure and
will cause cellular dehydration.21 Sorbitol level in
erythrocyte and ALR in the blood correlates with
level of plasma glucose.22 The increase of plasma
glucose level in hyperglycemia will increase the
sorbitol level.
Sorbitol is not easy to diffuse through cell
membrane, as a consequence sorbitol will
accumulate and disturb water entry inside the cell
and impair the osmotic.14 Sorbitol concentration raise
significantly in type 2 diabetic patients with DR,
compared to those type 2 diabetic patients without
complication. The sorbitol accumulation decreases
the number of pericyte of retina.23
The beneficial impact of strict glycemic control
to prevent diabetic complications has been reported.
However, most diabetic patients rarely achieve
consistent glucose level. Hence,  agents that can
prevent diabetic complications, irrespective of
glycemic control, would be an alternative.20 Aldose
reductase inhibitor and protein kinase inhibitor can
be included as an alternative treatment to prevent
diabetic complications. However, further study is
needed in order to obtain optimal benefit of these
agents.
CONCLUSION
C-106T polymorphism in ALR gene occured
in type 2 diabetic patients with DR on Dr. Sardjito
General Hospital Yogyakarta. There was no
significant difference on genotype frequency
between CC and CT  as well as C and T allele
between type 2 diabetic patients with or without
DR. Significant difference in osmotic erythrocyte
fragility was observed between CC and CT
genotype of type 2 diabetic patients, but there was
no significant difference between type 2 diabetic
patients with and without DR.  C-106T
polymorphism in ALR gene was a risk factor of DR
on type 2 diabetic patients.
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